A mouse model of Clostridium difficile-associated disease.

BACKGROUND & AIMS Infection with Clostridium difficile causes nosocomial antibiotic-associated diarrhea and colitis. Hamsters historically have been used to investigate disease pathogenesis and treatment, but are not ideal models because of the lack of hamster-specific reagents and genetically modified animals, and because they develop fulminant disease. The aim of this study was to establish a mouse model of antibiotic-induced C. difficile-associated disease (CDAD) that more closely resembles human disease. METHODS C57BL/6 mice were exposed to a mixture of antibiotics (kanamycin, gentamicin, colistin, metronidazole, and vancomycin) for 3 days. Two days later, they were given injections of clindamycin and then challenged 1 day later with different doses of C. difficile. RESULTS Mice that were exposed to antibiotics and then challenged with C. difficile developed diarrhea and lost weight. Disease severity varied from fulminant to minimal in accordance with the challenge dose. Typical histologic features of CDAD were evident. Oral vancomycin prevented CDAD in all mice, but 68% died from colitis after treatment was discontinued. All animals that survived an initial episode of CDAD showed no evidence of diarrhea or colitis after subsequent rechallenge with C. difficile. Different strains of C. difficile tested in the model showed different levels of virulence in mice. CONCLUSIONS We have developed a mouse model of CDAD that closely represents the human disease. In light of the recent substantial increases in CDAD incidence and severity, this model will be valuable in testing new treatments, examining disease pathogenesis, and elucidating mechanisms of protective immunity.

[1]  T. Monath,et al.  Evaluation of formalin-inactivated Clostridium difficile vaccines administered by parenteral and mucosal routes of immunization in hamsters , 1995, Infection and immunity.

[2]  J. Silva,et al.  Mucosal damage mediated by clostridial toxin in experimental clindamycin-associated colitis. , 1980, Gut.

[3]  J. Ketley,et al.  Effect of toxin A and B of Clostridium difficile on rabbit ileum and colon. , 1986, Gut.

[4]  S. Schnitt,et al.  Massive mural edema in severe pseudomembranous colitis. , 1983, Archives of pathology & laboratory medicine.

[5]  C. Pothoulakis,et al.  Direct evidence of mast cell involvement in Clostridium difficile toxin A-induced enteritis in mice. , 1998, Gastroenterology.

[6]  C. Pothoulakis,et al.  Comparative Efficacies of Rifaximin and Vancomycin for Treatment of Clostridium difficile-Associated Diarrhea and Prevention of Disease Recurrence in Hamsters , 2008, Antimicrobial Agents and Chemotherapy.

[7]  J. Gerberding,et al.  Severe Clostridium difficile-associated disease in populations previously at low risk--four states, 2005. , 2005, MMWR. Morbidity and mortality weekly report.

[8]  J. Silva,et al.  Antibiotic-associated colitis: effects of antibiotics on Clostridium difficile and the disease in hamsters. , 1979, Reviews of infectious diseases.

[9]  K. Horton,et al.  Pseudomembranous colitis: spectrum of imaging findings with clinical and pathologic correlation. , 1999, Radiographics : a review publication of the Radiological Society of North America, Inc.

[10]  E. Jennische,et al.  Enterotoxins from Clostridium difficile; diarrhoeogenic potency and morphological effects in the rat intestine. , 1990, Gut.

[11]  C. Pothoulakis,et al.  Rifalazil Treats and Prevents Relapse of Clostridium difficile-Associated Diarrhea in Hamsters , 2004, Antimicrobial Agents and Chemotherapy.

[12]  J. Silva,et al.  Clindamycin-induced enterocolitis in hamsters. , 1978, The Journal of infectious diseases.

[13]  C. Pothoulakis,et al.  Neutrophil recruitment in Clostridium difficile toxin A enteritis in the rabbit. , 1994, The Journal of clinical investigation.

[14]  K. Wilson,et al.  Gnotobiotic models for study of the microbial ecology of Clostridium difficile and Escherichia coli. , 1986, The Journal of infectious diseases.

[15]  D. Gerding,et al.  Infection of hamsters with epidemiologically important strains of Clostridium difficile. , 2001, The Journal of infectious diseases.

[16]  L. Peterson,et al.  Fatal Pseudomembranous Colitis Associated with a Variant Clostridium difficile Strain Not Detected by Toxin A Immunoassay , 2001, Annals of Internal Medicine.

[17]  K. Wilson,et al.  Suppression of Clostridium difficile by Normal Hamster Cecal Flora and Prevention of Antibiotic-Associated Cecitis , 1981, Infection and immunity.

[18]  J. Ballard,et al.  Identification of Clostridium difficile toxin B cardiotoxicity using a zebrafish embryo model of intoxication , 2006, Proceedings of the National Academy of Sciences.

[19]  C. Kelly,et al.  Update on Clostridium difficile associated disease , 2007, Current opinion in gastroenterology.

[20]  Robert B. Mandell,et al.  Human Monoclonal Antibodies Directed against Toxins A and B Prevent Clostridium difficile-Induced Mortality in Hamsters , 2006, Infection and Immunity.

[21]  C. Donskey,et al.  Effect of Antibiotic Treatment on Growth of and Toxin Production by Clostridium difficile in the Cecal Contents of Mice , 2005, Antimicrobial Agents and Chemotherapy.

[22]  N. Glaichenhaus,et al.  Priming by Microbial Antigens from the Intestinal Flora Determines the Ability of CD4+ T Cells to Rapidly Secrete IL-4 in BALB/c Mice Infected with Leishmania major1 , 2000, The Journal of Immunology.

[23]  T. Jodlowski,et al.  Emerging Therapies in the Treatment of Clostridium difficile–Associated Disease , 2006, The Annals of pharmacotherapy.

[24]  J. Bartlett,et al.  Clostridium difficile in gnotobiotic mice , 1980, Infection and immunity.

[25]  L. Mcfarland Alternative treatments for Clostridium difficile disease: what really works? , 2005, Journal of medical microbiology.

[26]  A. Limaye,et al.  Pseudomembranous Colitis Caused by a Toxin A− B+ Strain of Clostridium difficile , 2000, Journal of Clinical Microbiology.

[27]  C. Pothoulakis,et al.  Purification and properties of Clostridium difficile cytotoxin B. , 1986, The Journal of biological chemistry.

[28]  Kunitomo Watanabe,et al.  Identification of Toxin A-Negative, Toxin B-Positive Clostridium difficile by PCR , 1998, Journal of Clinical Microbiology.

[29]  C. Kelly,et al.  Asymptomatic carriage of Clostridium difficile and serum levels of IgG antibody against toxin A. , 2000, The New England journal of medicine.

[30]  C. Pothoulakis,et al.  Anti-Clostridium difficile bovine immunoglobulin concentrate inhibits cytotoxicity and enterotoxicity of C. difficile toxins , 1996, Antimicrobial agents and chemotherapy.

[31]  K. Saum,et al.  Effects of Clostridium difficile toxins given intragastrically to animals , 1985, Infection and immunity.

[32]  C. Kelly,et al.  Association between antibody response to toxin A and protection against recurrent Clostridium difficile diarrhoea , 2001, The Lancet.

[33]  C. Pothoulakis,et al.  IL-8 release and neutrophil activation by Clostridium difficile toxin-exposed human monocytes. , 1997, The American journal of physiology.

[34]  K. Sunakawa,et al.  Experimental models of Clostridium difficile enterocolitis in gnotobiotic mice. , 1985, Progress in clinical and biological research.

[35]  J. Kink,et al.  Antibodies to Recombinant Clostridium difficile Toxins A and B Are an Effective Treatment and Prevent Relapse of C. difficile-Associated Disease in a Hamster Model of Infection , 1998, Infection and Immunity.

[36]  F. Knoop Clindamycin-associated enterocolitis in guinea pigs: evidence for a bacterial toxin , 1979, Infection and immunity.

[37]  D. Bobak,et al.  Roles of intracellular calcium and NF-kappa B in the Clostridium difficile toxin A-induced up-regulation and secretion of IL-8 from human monocytes. , 1999, Journal of immunology.

[38]  G. Corthier,et al.  Interrelationships between digestive proteolytic activities and production and quantitation of toxins in pseudomembranous colitis induced by Clostridium difficile in gnotobiotic mice , 1989, Infection and immunity.

[39]  C. Kelly,et al.  Health care costs and mortality associated with nosocomial diarrhea due to Clostridium difficile. , 2002, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[40]  T. Monath,et al.  Serum Antitoxin Antibodies Mediate Systemic and Mucosal Protection from Clostridium difficileDisease in Hamsters , 1999, Infection and Immunity.

[41]  W. J. Johnson,et al.  Pseudomembranous colitis in Clostridium difficile-monoassociated rats , 1983, Infection and immunity.